Introduction
Every year about 500,000 deaths, mostly children under the age of five, result from nearly 200 million cases of malaria (World Health Organization, 2014) . In Southeast Asia, P. falciparum parasites have developed resistance to current first-line artemisinin-based combination therapies (ACT) (Uhlemann and Fidock, 2012; Ariey et al., 2014; Ashley et al., 2014; Burrows et al., 2014; Straimer et al., 2015) . Therefore, it is essential to identify new drug targets to facilitate the development of novel antimalarial drugs.
The Plasmodium parasite purine import pathway is one potential target, because the parasites are purine auxotrophic and require imported purines to synthesize RNA and replicate DNA during proliferation in the human host. The parasites import purines via equilibrative nucleoside transporters (Baldwin et al., 2004; Downie et al., 2008; Riegelhaupt et al., 2010; Frame et al., 2015a) . In P. falciparum, knockout of the primary purine transporter, PfENT1, is conditionally lethal at purine concentrations found in human blood, <10 μ M (Traut, 1994; El Bissati et al., 2006; Frame et al., 2015b) . Thus, we and others hypothesized that small molecule inhibitors of the parasite purine transporter would kill malaria parasites (El Bissati et al., 2006; Baldwin et al., 2007; El Bissati et al., 2008; Frame et al., 2015a) . We developed a robust, yeastbased HTS to identify PfENT1 inhibitors (Frame et al., 2015b) . The basis for the HTS was that 5-flurouridine (5-FUrd) is cytotoxic for PfENT1-expressing fui1Δ yeast due to 5-FUrd entry via PfENT1. With 5-FUrd in the growth media, PfENT1-expressing fui1Δ yeast will only grow if a PfENT1 inhibitor is present in the media. We screened 64,500 compounds, identified 171 hits, field isolates (Deniskin et al., 2016) . Collectively, these finding support the hypothesis that PfENT1 inhibitors may be developed into novel antimalarial drugs.
P. berghei causes malaria in mice. It is currently the best animal model to study the human disease, although significant differences have been noted between human P. falciparum malaria and the P. berghei mouse model (Chisholm et al., 2016) . PbENT1 is 60% amino acid sequence identical with PfENT1 (Supplemental Fig. 1 ). Mice infected with PbENT1-knockout P.
berghei ANKA parasites develop a non-fatal, high parasitemia without cerebral malaria symptoms (Niikura et al., 2013) . However, knockouts of other P. berghei genes that reduce parasite viability also cause loss of the ability to induce cerebral malaria (Chisholm et al., 2016) .
Thus, the inability to induce cerebral malaria may not be related to the PbENT1 knockout, but rather could reflect the loss of parasite fitness. Loss of fitness after ENT1 knockout is also seen in mice infected with ENT1-disrupted P. yoelii, another murine malaria species. They do not develop obvious infection but develop sterilizing immunity against subsequent infection with wild-type (WT) P. yoelii (Aly et al., 2010) . The limited viability of ENT1-knockout murine-infective Plasmodia indicates that they have a secondary purine import pathway. This pathway plus higher mouse blood purine concentrations, presumably allows the ENT1-knockout parasites to remain viable during in vivo infection, albeit with reduced pathogenicity.
Adenosine uptake into human RBCs is mediated by human ENT1 (hENT1) (Domin et al., 1988; Griffiths et al., 1997) . hENT1 is 17-18% amino acid sequence identical to PbENT1 and PfENT1. It is inhibited by nitrobenzylmercaptopurineriboside (NBMPR) and the FDA approved drug, dipyridamole at nanomolar concentrations (Domin et al., 1988; Griffiths et al., 1997) . Neither NBMPR nor dipyridamole inhibit PfENT1 at concentration up to 20 Carter et al., 2000a; Parker et al., 2000; Riegelhaupt et al., 2010) . Thus, it may be feasible to develop inhibitors with high specificity for malaria ENT1s. The existence of known nanomolar potency hENT1 inhibitors indicates that the ENTs are druggable targets.
This article has not been copyedited and formatted. The final version may differ from this version. In this paper, we expressed PbENT1 in Saccharomyces cerevisiae and characterized its substrate specificity profile. We investigated whether our PfENT1 inhibitors block PbENT1-mediated transport and their effects on the human RBC ENT1 homologue. We show that PbENT1 is a purine and pyrimidine transporter. We found that the PfENT1 inhibitors inhibit PbENT1 with similar nanomolar affinities, but with 10-1,000-fold lower affinity for hENT1. Thus, following the development of more potent PfENT1 inhibitors, the in vivo mouse malaria model may be useful to test their efficacy.
This article has not been copyedited and formatted. The final version may differ from this version. Yeast Strains and Transformation. DNA constructs were transformed into purine auxotrophic yeast as previously described (Frame et al., 2015b) . Briefly, S. cerevisiae BY4741 with FUI1 and ADE2 gene deletions were used as WT (MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0; fui1Δ::KanMX4; ade2Δ::hphNT1) . Hereafter, this yeast strain is referred to as purine auxotrophic yeast. Yeast were transformed using the lithium-acetate/DMSO method (Hill et al., 1991) . WT yeast were grown in 10 ml YPD media to a cell density of 2 x 10 7 cells/ml. Cells were pelleted and washed with 20 ml cold lithium acetate (LiOAc: 100 mM LiOAc, 10 mM Tris pH 8).
Pellet was resuspended in 100 µl LiOAc, and 10 µl of salmon-sperm DNA (2 mg/ml) and 1 µg of DNA construct was added. After incubation at room temperature for 5 min, 280 µl 50% PEG (polyethylene glycol 3350; %w/v) was added. Final solution was incubated at 30°C for 45 min.
This article has not been copyedited and formatted. The final version may differ from this version. 
harvester (#96-3-469, Hamden, CT). Filtermats were dried for > 1 h and sealed in plastic bags containing 5 ml Betaplate Scint LSC (Perkin Elmer). Filtermats were counted using 1450
Microbeta Trilux (Perkin Elmer). IC 50 values were calculated using Prism 6 (GraphPad Software). All experiments were repeated at least three times on different days.
Inhibition of PbENT1 by PfENT1 inhibitors. PbENT1-HA-expressing purine auxotrophic yeast were grown to mid-log phase in SDM + 1 mM adenosine. Cells were washed and resuspended to a concentration of 2 x 10 8 cells/ml as above. A 96-well plate was preloaded with 100 µl of 100 nM [ 3 H]adenosine. 0.5 µl of compound, serially diluted in DMSO, was added to each well. 100 µl of cells were added and cells were harvested after 15 min, as above.
Compounds were also tested on PfENT1-expressing purine auxotrophic yeast as described in Chemical structure and composition of PfENT1 inhibitors was validated previously by NMR and mass spectrometry (Frame et al., 2015b) . All experiments were repeated at least three times on different days.
Ex vivo parasite drug susceptibility assay. Donor outbred CD1 mice (female, 6-8 weeks of age; Charles River Laboratories, Stone Ridge, NY), were infected with 1 ×10 7 P.
berghei parasites (strain ANKA 676m1cl1). This strain was obtained from the BEI Resources Repository, NIAID, NIH, as item MRA-868, contributed by Chris J. Janse and Andrew P.
Waters. Once the parasitemia reached 5-7%, the parasites were harvested by cardiac puncture. 1 ml of the harvested blood was incubated in 50 ml RPMI1640 malaria culture medium (supplemented with 25% fetal bovine serum ) with gentle shaking and incubated at 36.8°C for 23 hr (Janse et al., 2006) . The parasites were then pelleted, washed in physiological saline solution, and reinjected (in saline solution, total volume 0.5 ml) into another mouse by tail This article has not been copyedited and formatted. The final version may differ from this version. 
Results
PbENT1 shares 60% amino acid identity with PfENT1 (Supplemental Fig. 1 ), so we hypothesized that PbENT1 should have a similar substrate transport profile. Because
Plasmodium genes are often A-T rich, heterologous expression is often difficult. To eliminate effects of codon-usage bias on expression, we used a yeast codon-optimized version of PbENT1 (Supplemental Fig. 2 ). The expression vector was transformed into yeast lacking the endogenous uridine transporter, FUI1 and one of the enzymes in the de novo purine synthesis pathway, ADE2. Growth of these purine auxotrophic yeast can be rescued in media containing adenine, which can enter via the endogenous yeast FCY2 transporter (Weber et al., 1990 values for four purine nucleosides and their equivalent nucleobases (Fig. 3 ). All of the tested This article has not been copyedited and formatted. The final version may differ from this version. 2) . We tested the ability of six pyrimidine nucleosides and their equivalent nucleobases to inhibit [ 3 H]adenosine uptake (Fig. 4) . The nucleosides thymidine and uridine showed the highest affinity with IC 50 values of 91.3 μ M and 400 µM, respectively) ( Table 1 ). The nucleobase cytosine and nucleoside cytidine were unable to completely inhibit radiolabel uptake, even at the maximum concentration tested, 12.5 mM (Fig. 4) .
Recently we identified and characterized nine small molecule inhibitors of PfENT1 (Table 2 ) (Frame et al., 2015b) . We showed that these compounds inhibit [ 3 H]adenosine uptake into erythrocyte-free P. falciparum parasites and kill parasites in culture (Frame et al., 2015b) . In the present study, we tested their ability to inhibit [ 3 H]adenosine uptake into PbENT1-HAexpressing yeast (Fig. 5 ). All nine compounds inhibited PbENT1 with IC 50 values in the 3 to 60 nM range (Table 2 ). The ratios of PbENT1 IC 50 to PfENT1 IC 50 for the different compounds were all within a factor of 2 (Table 2) . Thus, the compounds have similar efficacy against both transporters despite the 40% amino acid sequence differences.
Based on the ability of the PfENT1 inhibitors to block PbENT1, we sought to test the hypothesis that they would inhibit proliferation of P. berghei parasites. It should be noted that (Table 3) . Amodiaquine, 4-aminoquinoline compound similar to chloroquine, was included as a positive control (Table 3) .
Similar IC 50 values were obtained for inhibition of P. falciparum parasite proliferation in culture (Table 3) .
This article has not been copyedited and formatted. The final version may differ from this version. We also tested the specificity of the PfENT1 inhibitors relative to the human erythrocyte hENT1 purine transporter. We assessed their effect using uninfected human RBCs where hENT1 function was assayed by [ 3 H]adenosine uptake (Fig. 6A ). Compound 7 displayed the lowest selectivity -it had 27 times higher affinity for PfENT1 than for hENT1 (Fig. 6B) .
Compound 1 had the highest selectivity, it inhibited hENT1 at a concentration 1200 times higher than the concentration at which it inhibited PfENT1 (Fig. 6B) . These results confirmed that the compounds displayed significant specificity for PfENT1 over the human erythrocyte hENT1
transporter.
Discussion
The long term goal of this project is to develop antimalarial drugs against a novel target, the primary purine import transporter. As a step towards that goal, in the current work we sought to determine the feasibility of using the mouse malaria model. To establish the feasibility of using the mouse model, we characterized the functional properties of PbENT1 and determined whether the best hits from our HTS for PfENT1 inhibitors would also work on the P. berghei homologue, PbENT1. PbENT1, like its homologues in P. falciparum and P. vivax (Riegelhaupt et al., 2010; Deniskin et al., 2016) , transports both purines and pyrimidines (Fig. 2, Table 1 ).
PbENT1 has higher affinity for purines compared to pyrimidines and higher affinity for nucleosides compared to nucleobases (Table 1) . Inosine and guanosine showed the highest affinities (Table 1) , much like the Leishmania LdNT2 nucleoside transporter (Carter et al., 2000b ). For P. falciparum, adenosine and hypoxanthine are the preferred substrates for purine import, as these purines are present at the highest concentration in human plasma and are also present in human erythrocytes (Moser et al., 1989; Traut, 1994) . The inhibition constants (K i ) for PfENT1 transport of adenosine and hypoxanthine are around 650 µM and 300 µM, respectively (Riegelhaupt et al., 2010) . In contrast, for PbENT1 the IC 50 values were 4-to-6 fold lower for these substrates (Table 1) . The different affinities for various purines are presumably due to amino acid differences between PfENT1 and PbENT1, as they are only 60% sequence identical. Whether these differences in substrate affinity are physiologically significant is unknown at present. Of note, differences exist in the purine import pathways of Plasmodium species that infect primates and rodents. Genome sequencing reveals that P. vivax and P.
falciparum encode 4 ENT homologues (ENT 1-4), while the species that infect rodents, P.
berghei and P. yoelii, lack an ENT3 orthologue (Frame et al., 2012; Frame et al., 2015a suggests that there may be differences in purine transport and metabolism between rodents and humans that may be important for proliferation of the respective Plasmodium species.
Efforts to combat malaria have been hampered by the development of resistance to antimalarial drugs (Sa et al., 2011) . Thus, it is important to have a robust pipeline of new therapeutics that target novel aspects of Plasmodium parasite biology to replace current drugs as they become less effective (Burrows et al., 2014) . One potential target is the purine import and salvage pathway, which is essential for parasite survival (Ducati et al., 2013; Frame et al., 2015a) . Using a yeast-based HTS, we previously identified compounds that inhibit PfENT1 at concentrations in the nanomolar range (Frame et al., 2015b) . We characterized nine of the hits in a series of secondary assays and showed that they inhibit P. falciparum parasite proliferation in culture. In this paper, we show that despite the 40% amino acid sequence differences between PbENT1 and PfENT1, these nine inhibitors also block PbENT1-mediated purine transport with IC 50 values comparable to those for PfENT1 (Table 2) .
Ideally, an antimalarial drug would not inhibit hENT1. However, dipyridamole, an FDA approved drug, that inhibits hENT1 has been safely used in patients (Griffiths et al., 1997) .
Thus, avoiding interactions with hENT1 may not be essential for a viable antimalarial drug targeting PfENT1. None the less, because hENT1 is only 17% amino acid sequence identical with PfENT1 and dipyridamole does not block PfENT1 (Riegelhaupt et al., 2010) , it may be feasible to identify inhibitors that display specificity for PfENT1 over hENT1. In fact, the PfENT1 inhibitors that we have identified have lower potency against the human RBC purine transporters, hENT1 (Fig. 6) . They are 27 to 1,200-fold more potent against the Plasmodium ENT1 homologues relative to the human hENT1 (Fig. 6B) . Thus, it may be possible to maintain selectivity for the Plasmodium ENTs during the hit-to-lead medicinal chemistry process that will be necessary to develop our current compounds into antimalarial drugs.
Based on the assumption that PbENT1-mediated purine import is essential for P.
berghei parasite proliferation, we expected that the PfENT1 inhibitors would kill P. berghei parasites. Because these compounds are HTS hits that need to be optimized through medicinal chemistry, we did not think it worthwhile to determine the mouse pharmacokinetics for these compounds at this time. Thus, we did not test the efficacy of the inhibitors in P. berghei infected mice. To assess their efficacy on parasite proliferation, we tested the effect of three of the inhibitors on P. berghei parasite proliferation in ex vivo culture (Table 3 ). The inhibitors blocked parasite proliferation with IC 50 values similar to their efficacy against P. falciparum parasites in culture (Frame et al., 2015b) . This suggests that with improved potency through medicinal chemistry efforts, Plasmodium ENT1 inhibitors will display efficacy in the in vivo mouse malaria model.
One strategy to reduce the development of resistance to antimalarial drugs has been to pair drugs with different targets. This was the rationale behind pairing artemisinin derivatives with other drugs in ACTs. Unfortunately, because the partner drugs for the artemisinins already had been widely used, resistance to the partner drugs was already present in the P. falciparum parasite population. This has contributed to the development of resistance to the artemisinin component of the ACTs (Uhlemann and Fidock, 2012; Ariey et al., 2014; Ashley et al., 2014; Burrows et al., 2014; Straimer et al., 2015) . With our PfENT1 inhibitors, we were surprised that PfENT1-knockout parasites grown in high purine concentrations were also killed by the PfENT1 inhibitors with 2 to 4 fold higher IC 50 values (Frame et al., 2015b) . Killing of PfENT1-knockout parasites showed a delayed-death phenotype not observed in the killing of the WT parasites (Frame et al., 2015b) . This indicates that the secondary target causing death in the PfENT1-knockout parasites is distinct from the primary target in WT parasites. The existence of two targets with similar affinities may reduce the likelihood of parasites developing resistance to these compounds. Whether the affinity for both targets can be improved simultaneously during medicinal chemistry optimization is uncertain. An alternative strategy might be to pair a PfENT1 inhibitor with another drug that acts elsewhere in the purine salvage pathway. Schramm and coworkers have shown that transition state analogue inhibitors of the purine salvage pathway This article has not been copyedited and formatted. The final version may differ from this version. enzyme, purine nucleoside phosphorylase (PNP), kill malaria parasites (Cassera et al., 2011; Ducati et al., 2013) . Targeting two points in the purine metabolic pathway might lead to synergistic effects. Future experiments will be necessary to test this hypothesis. In summary, we
showed that the PfENT1 inhibitors were active against PbENT1 and that they were able to inhibit the proliferation of P. berghei parasites in ex vivo culture. This indicates that we will be able to utilize the mouse malaria model to test the utility of inhibition of purine uptake as a strategy for development of novel antimalarial drugs.
This article has not been copyedited and formatted. The final version may differ from this version. shown is the average of three independent experiments. OD 600 , optical density at 600 nm. Table 1 . Data from a representative experiment is shown. substrates, only uridine and thymidine showed complete inhibition. IC 50 values are shown in Table 1 . Data from a representative experiment is shown. Table 2 . et al. (2015b) . Note that the y-axis is a log scale.
